Immune checkpoint inhibitors have demonstrated significant benefits in treating various
types of tumors. However, a considerable number of patients do not respond to this therapy …

Immune checkpoint inhibitors (ICIs) have generated durable clinical responses in multiple
tumor types, but their therapeutic efficacy is limited by development of primary or acquired …

Despite the promise of immunotherapy for cancer treatment, nearly 80% of patients fail to
respond to checkpoint inhibitor (CPI) therapy. Regulatory T cells (Tregs), which inhibit …

Abstract Background: Tumor-infiltrating CD4+ FOXP3+ regulatory T cells (Tregs) are a major
driver of the immunosuppressive tumor microenvironment. CC chemokine receptor 8 …

Abstract Background: Tumor-infiltrating Tregs (TITR) constitute a sub-family of immuno-
suppressive cells abundantly found in multiple solid cancers. They play a critical role in …

Therapeutic Rationale For Targeting CCR8 In Cancer Immunization and Screening S Page 1
Novel Monoclonal Antibodies (mAbs) Targeting Human CCR8 Provide Potential Candidates …

Background CC chemokine receptor 4 (CCR4) represents a potentially important target for
cancer immunotherapy due to its expression on tumor infiltrating immune cells including …

Background Depletion of tumor-resident CCR8+ Treg cells has been demonstrated
remarkable antitumor effects. A few hCCR8-targeted therapeutic antibodies have been …

Background Regulatory T cells (Tregs) are suppressive immune cells required for the
maintenance of immune homeostasis, but tumor-infiltrating Tregs are known to suppress the …

The presence of T regulatory (Treg) cells in the tumor microenvironment is associated with
poor prognosis and resistance to therapies aimed at reactivating anti-tumor immune …